A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Withdrawn
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
0actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Strategic considerations
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-05 | actual | When the study began enrolling |
| Primary completion | 2025-07-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-28 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-06-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Intervention
- Drug: Venetoclax
Primary outcomes
what the primary-completion date above is the date OFMaximum Observed Plasma Concentration (Cmax) of Venetoclax
measured Up to Day 27
Time to Cmax (Tmax) of Venetoclax
measured Up to Day 27
Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to the Last Measurable Concentration (AUCt) of Venetoclax
measured Up to Day 27
AUC from Time 0 to Infinity (AUCinf) of Venetoclax
measured Up to Day 27
Apparent Terminal Phase Elimination Rate Constant (β, BETA) of Venetoclax
measured Up to Day 27
Terminal Phase Elimination Half-life (t1/2) of Venetoclax
measured Up to Day 27
Number of Adverse Events (AEs)
measured Baseline to Day 57
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed